ABOUT US
VCARE PHARMATECH
Jiangsu Vcare PharmaTech Co., Ltd.(Jiangsu Vcare), established in 2010, is a high-tech biopharmaceutical company dedicated to addressing unmet clinical needs through differentiated innovation in drug and advanced therapy development. Since our inception, we’ve experienced rapid growth and evolved into a group-style enterprise with a strong foundation in two core business segments: innovative drug R&D and comprehensive pharmaceutical industry chain services. With 15 years of experience and a forward-looking mindset, Jiangsu Vcare continues to shape the future of biopharma through technology, quality, and purpose-driven innovation.
INNOVATIVE DRUGS
Jiangsu Vcare's proprietary innovative drug R&D business adheres to a differentiated strategy addressing unmet clinical needs. Based on innovative approaches including "overcoming therapeutic resistance", "resolving drug resistance", and "enhancing target selectivity", the company has established a tiered pipeline architecture centered on Vicagrel. Currently, it possesses five Class I innovative drugs in clinical development: VC004 capsules (oral anti-tumor targeted therapy); Vicagrel capsules (oral anti-thrombotic agent); VC005 tablets (oral immunomodulatory and anti-inflammatory agent); VC005 gel (topical immunomodulatory and anti-inflammatory formulation). Additionally, multiple preclinical projects are progressing through the pipeline, with therapeutic focuses spanning cardiovascular/cerebrovascular diseases, oncology, and autoimmune/inflammatory disorders. This strategic portfolio positions the company for comprehensive coverage of global pharmaceutical markets in the future.
INNOVATION PLATFORM
Innovative Drugs - Medicine - Pharmacy - Chemistry; Covering The Entire Life Cycle Of New Drug Research And Development
NEWS
Capital Empowers Innovation: Vcare PharmaTech Completes Nearly RMB 200 Million Series C3 Financing
2026-06-03
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) has successfully closed its Series C3 financing totaling nearly RMB 200 million. The round was led by existing shareholder Hongcheng Investment, with follow-on investments from institutions including Xinghe Venture Capital, Hangzhou Jinlong, Hongyao Kechuang and Huadian Investment. Meanwhile, the firm has onboarded high-caliber new investors such as Huafuruixing, consolidating a solid capital foundation for its sustainable long-term growth.
2026-05-13
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced that VC005 Topical Gel, its self-developed second-generation highly selective JAK1 inhibitor, has completed the enrollment of the first patient in the phase III clinical trial for the treatment of mild-to-moderate atopic dermatitis (AD).
2026-05-09
Recently, VC005 Topical Gel, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), has officially obtained the IND approval from the CDE of the NMPA. The product is intended for the topical treatment of non-segmental vitiligo.
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn